-

Monsanto Wins Appeal Ruling in Erickson v. Monsanto

Court remands PCB case back to trial court for further proceedings

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto’s favor on multiple grounds.

This decision reverses the initial verdict of $185 million in its entirety and remands the case back to trial court for further proceedings.

The company stated:

“This is a very significant ruling in favor of Monsanto because the Court of Appeals identified multiple errors - that cut across most Sky Valley Education Center (SVEC) trials that have been completed - including the unreliability of Plaintiffs’ exposure evidence that was erroneously admitted in all SVEC cases tried to date. Specifically, the Court of Appeals held that the trial court improperly denied the Company’s statute of repose defense, erroneously admitted a major portion of plaintiffs’ key expert exposure opinions, and wrongfully allowed punitive damages on plaintiffs’ post-sale failure to warn.

“The Company will consider its legal options regarding the application of this ruling to other SVEC verdicts that are in conflict with it, as well as how this ruling could affect future trials.”

The SVEC cases represent most of PCB-related personal injury litigation against Monsanto. Erickson is the first personal injury case to go to trial due to alleged PCB exposure at a single school in Washington state.

The evidence in these cases have demonstrated that all measured PCB air concentrations at SVEC fell well below the regulatory health-protective limits and guidelines set by state and federal regulators, and there is no evidence any such exposure to PCBs can and did cause the alleged injuries.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o...

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause.1 Through the partnership, Hart will share her personal experience with moderate to severe hot flashes due to menopause to help women recognize their symptoms and to encourage more proactive treatmen...

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...
Back to Newsroom